From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Zoetic – as the shares tumble again is it worth considering the matter of revenue recognition. You bet!

By Tom Winnifrith | Wednesday 19 May 2021


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Shares in the fraud Zoetic International (ZOE) are off again sharply today hitting a new year low of 56p. They are still about 55p overvalued and with 25% of the equity owned via CFDs there are going to be an awful lot of margin calls being issued as each new low is hit. That will create some forced selling so making this a sort of rolling maul which will see anyone dumb enough to keep holding racking up ever greater losses far more quickly than they might think. And thus at this juncture I ponder the issue of revenue recognition, now that Zoetic appears to have a bit of revenue. I say “appears” quite deliberately.

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Gold up Ariana down

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 17:47:06